Drug General Information (ID: DDIO7N92PX)
Drug Name			Cisapride		Drug Info		Methazolamide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Gastrointestinal Agents				Carbonic Anhydrase Inhibitors
Structure

Mechanism of Cisapride-Methazolamide Interaction (Severity Level: Major)
Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Drug Name		Cisapride				Methazolamide
Mechanism 1		Prolong QT interval				Hypokalemia
Key Mechanism Factor 1
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Cisapride and Methazolamide
Mechanism 2		Prolong QT interval				Hypomagnesemia
Key Mechanism Factor 2
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Cisapride and Methazolamide

Recommended Action
Management		Cisapride is contraindicated in patients with uncorrected hypokalemia and hypomagnesemia, such as those taking potassium-wasting diuretics.

References
1	Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.